Literature DB >> 12594813

Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha.

Anait S Levenson1, Barry D Gehm, Sandra Timm Pearce, Jun Horiguchi, Laura A Simons, James E Ward, J Larry Jameson, V Craig Jordan.   

Abstract

Resveratrol (Res) is a phytoestrogen found in grapes and present in red wine. Res has been shown to function as an estrogen receptor (ER) agonist, but it remains unclear whether it may also exert antagonist activity. Our aim was to study the effects of Res at both the molecular (TGFalpha gene activation) and the cellular (cell growth) levels in breast cancer cells stably transfected with wild-type (wt) ER(D351) and mutant (mut) ER (D351Y). TGFalpha mRNA induction was used as a specific marker of estradiol (E(2)) responsiveness. Res caused a concentration-dependent (10(-8)-10(-4) M) stimulation of TGFalpha mRNA, indicating that it acts as an estrogen agonist in these cell lines. The pure antiestrogen ICI 182,780 (ICI) blocked Res-induced activation of TGFalpha, consistent with action through an ER-mediated pathway. Further studies that combined treatments with E(2) and Res showed that Res does not act as an antagonist in the presence of various (10(-11)-10(-8) M) concentrations of E(2). To determine whether Res can be classified as a type I or type II estrogen (Jordan et al., Cancer Res 2001;61:6619-23,), we examined Res with the D351G ER in the TGFalpha assay and found that Res belongs to the type I estrogens. Both Res and E(2) had concentration-dependent growth inhibitory effects in cells expressing wtER and D351Y ER. Although the pure antiestrogen ICI blocked the growth inhibitory effects of E(2), it did not block the inhibitory effects of Res, suggesting that the antiproliferative effects of Res also involve ER-independent pathways. Interestingly, Res differentially affected the levels of ER protein in these 2 cell lines: Res down-regulated wtER levels while significantly up-regulating the amount of mutD351Y ER. Co-treatment with ICI resulted in strongly reduced ER levels in both cell lines. Gene array studies revealed Res-induced up-regulation of more than 80 genes, among them a profound activation of p21(CIP1)/WAF1, a gene associated with growth arrest. The p21(CIP1)/WAF1 protein levels measured by Western blotting confirmed Res-induced significant up-regulation of this protein in both cell lines. In summary, Res acts as an ER agonist at low doses but also activates ER-independent pathways, some of which inhibit cell growth. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594813     DOI: 10.1002/ijc.10992

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  31 in total

1.  Longevity nutrients resveratrol, wines and grapes.

Authors:  Istvan Lekli; Diptarka Ray; Dipak K Das
Journal:  Genes Nutr       Date:  2009-09-04       Impact factor: 5.523

2.  Use of alpha-, beta-Estrogen Receptor as a "new tool" for detection of specific small molecule activity.

Authors:  Samir Kumar Gunjan; Dennis Trent Rogers; Jingxian Zhang; Kil-Young Yun; Deane L Falcone; John Littleton
Journal:  Plant Mol Biol Report       Date:  2015-03-26       Impact factor: 1.595

3.  Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor α expression in human breast cancer cells.

Authors:  Laura Macpherson; Jason Matthews
Journal:  Cancer Lett       Date:  2010-09-16       Impact factor: 8.679

4.  Trans-resveratrol boronic acid exhibits enhanced anti-proliferative activity on estrogen-dependent MCF-7 breast cancer cells.

Authors:  Venkata Mahidhar Yenugonda; Yali Kong; Tushar B Deb; Yonghong Yang; Rebecca B Riggins; Milton L Brown
Journal:  Cancer Biol Ther       Date:  2012-08-01       Impact factor: 4.742

5.  Estrogen receptor expression is required for low-dose resveratrol-mediated repression of aryl hydrocarbon receptor activity.

Authors:  Gary H Perdew; Brett D Hollingshead; Brett C Dinatale; J Luis Morales; Mark P Labrecque; Mandeep K Takhar; Kevin J Tam; Timothy V Beischlag
Journal:  J Pharmacol Exp Ther       Date:  2010-08-17       Impact factor: 4.030

6.  Identification of estrogen-responsive genes involved in breast cancer metastases to the bone.

Authors:  Jun Wang; Jennifer Jarrett; Chiang-Ching Huang; Robert L Satcher; Anait S Levenson
Journal:  Clin Exp Metastasis       Date:  2007-06-26       Impact factor: 5.150

7.  Significance of wine and resveratrol in cardiovascular disease: French paradox revisited.

Authors:  Ramesh Vidavalur; Hajime Otani; Pawan K Singal; Nilanjana Maulik
Journal:  Exp Clin Cardiol       Date:  2006

Review 8.  Resveratrol-loaded nanomedicines for cancer applications.

Authors:  Manjusha Annaji; Ishwor Poudel; Sai H S Boddu; Robert D Arnold; Amit K Tiwari; R Jayachandra Babu
Journal:  Cancer Rep (Hoboken)       Date:  2021-03-02

9.  Trans-, cis-, and dihydro-resveratrol: a comparative study.

Authors:  Natalia Yu Anisimova; Mikhail V Kiselevsky; Andrey V Sosnov; Sergey V Sadovnikov; Ivan N Stankov; Andrei A Gakh
Journal:  Chem Cent J       Date:  2011-12-20       Impact factor: 4.215

10.  Systemic administration of diarylpropionitrile (DPN) or phytoestrogens does not affect anxiety-related behaviors in gonadally intact male rats.

Authors:  Heather B Patisaul; Katherine T Burke; Ruth E Hinkle; Heather B Adewale; Damian Shea
Journal:  Horm Behav       Date:  2008-11-21       Impact factor: 3.587

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.